Cantor Fitzgerald initiated coverage of Astria Therapeutics (ATXS) with an Overweight rating and $47 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS:
- Astria Therapeutics price target raised to $28 from $27 at Wedbush
- Astria Therapeutics Advances Clinical Trials and Financials
- Astria Therapeutics: Promising Developments and Strategic Advancements Justify Buy Rating
- Astria Therapeutics: Promising Pipeline and Strong Financials Drive Buy Rating
- Buy Rating for Astria Therapeutics: Promising Clinical Advancements and Strong Financial Position
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue